Figure 2.
Best overall response. (A) Best overall response rates as assessed by the investigator in the all-treated population and patients without del(17p) or with del(17p)/mutated TP53. (B) Forest plots of investigator-assessed CR rates across patient subgroups by baseline characteristics in the all-treated population. DOCR, duration of CR; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; ORR, overall response rate; nPR, nodular partial response; PR, partial response. *After achieving CR, 9 patients with <1 year of follow-up were not evaluable; 1 patient died of cardiac arrest 7 months after initial CR and 47 days after completion of therapy. †Per Döhner hierarchy. ‡Proportion of patients with CR or CRi.